<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hypomethylating drugs are useful in the management of <z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo>, but there are only few reports on <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocycitic (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>We describe our experience in 3 CMML patients treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start </plain></SENT>
</text></document>